Cyxone AB

CYXO

SE0007815428

Pharmaceuticals

Delayed Nasdaq Stockholm Other stock markets 09:45:19 2024-05-16 am EDT			5-day change	1st Jan Change
0.1275 ^SEK	+6.69%		+16.44%	+26.99%

Apr. 22	Sweden's Cyxone Appoints New CEO	MT
Apr. 22	Cyxone AB Announces Chief Executive Officer Changes	CI

Cyxone AB Appoints Ola Skanung as Senior Executive Advisor

June 09, 2021 at 09:51 am EDT

Cyxone AB (publ) announced that Ola Skanung takes on the role of senior executive advisor in Cyxone and will continue to work within the company's management team.

Latest news about Cyxone AB

Sweden's Cyxone Appoints New CEO	Apr. 22	MT
Cyxone AB Announces Chief Executive Officer Changes	Apr. 22	CI
Cyxone Enters Research Deal for Rheumatoid Arthritis Therapy	Mar. 25	MT
Cyxone Enters Important Research Collaboration with University of Glasgow	Mar. 25	CI
Cyxone AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Cyxone Reaches an Important Milestone for the Drug Candidate Rabeximod	Jan. 15	CI
Cyxone AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Cyxone to Receive Unitary Patent in EU for T20K Drug Candidate	23-10-09	MT
Cyxone AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Sweden's Cyxone Updates Development Plan for Rheumatoid Arthritis Drug	23-08-30	MT
Cyxone Revises Strategy for Commercial Alignment Targeting Valuable Market Opportunities	23-08-29	CI
Cyxone Announces CFO Changes	23-06-15	CI
EU to Grant Cyxone Divisional Patent for Multiple Sclerosis Drug Candidate	23-05-31	MT
Cyxone AB Announces Board Changes	23-05-30	CI
Cyxone AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Sweden’s Cyxone Secures US Patent Approval for Rabeximod Compound	23-05-09	MT
Cyxone AB Announces Board Resignations	23-04-26	CI
Cyxone AB Receives Notice of Allowance from the US Patent Office for the Protection of Rabeximod Compounds	23-04-02	CI
Cyxone AB Makes Significant Progress in the Manufacturing Process for Rabeximod	23-03-09	CI
Cyxone AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Cyxone AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Cyxone Wins Georgian Nod for Phase 2b Study for Rheumatoid Arthritis Drug	23-02-09	MT
Cyxone AB Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA	23-02-09	CI
Cyxone Completes National Filings for Arthritis Drug Patents	23-02-06	MT
Cyxone AB Advances the Patent Portfolio for Rabeximod	23-02-06	CI

Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The Company's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The Company has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CYXONE AB	+26.99%	2.42M
KYOWA KIRIN CO. LTD.	+11.98%	9.08B
SK BIOPHARMACEUTICALS CO., LTD.	-12.85%	5.06B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+54.35%	4.85B
YUHAN CORPORATION	+1.60%	3.85B
INDIVIOR PLC	+13.25%	2.37B
BETTA PHARMACEUTICALS CO., LTD.	-20.85%	2.36B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.62%	2.27B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.25%	2.22B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Cyxone AB

Equities

CYXO

SE0007815428

Pharmaceuticals

Cyxone AB Appoints Ola Skanung as Senior Executive Advisor

Latest news about Cyxone AB

Chart Cyxone AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals